194 related articles for article (PubMed ID: 31187121)
1. Ovarian cancer and the evolution of subtype classifications using transcriptional profiling†.
Cook DP; Vanderhyden BC
Biol Reprod; 2019 Sep; 101(3):645-658. PubMed ID: 31187121
[TBL] [Abstract][Full Text] [Related]
2. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
3. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.
Barnes BM; Nelson L; Tighe A; Burghel GJ; Lin IH; Desai S; McGrail JC; Morgan RD; Taylor SS
Genome Med; 2021 Sep; 13(1):140. PubMed ID: 34470661
[TBL] [Abstract][Full Text] [Related]
4. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
[TBL] [Abstract][Full Text] [Related]
5. [Can new molecular profiles in epithelial ovarian cancer modify therapeutics?].
Lavoué V; Rousselin A; Delplanque S; Pinsard M; Henno S; Foucher F; Levêque J; de la Motte Rouge T
J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):107-112. PubMed ID: 28403964
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Talhouk A; George J; Wang C; Budden T; Tan TZ; Chiu DS; Kommoss S; Leong HS; Chen S; Intermaggio MP; Gilks B; Nazeran TM; Volchek M; Elatre W; Bentley RC; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; Leong SCY; Liu G; Johnson D; Chen B; Group A; Alsop J; Banerjee SN; Behrens S; Bodelon C; Brand AH; Brinton L; Carney ME; Chiew YE; Cushing-Haugen KL; Cybulski C; Ennis D; Fereday S; Fortner RT; García-Donas J; Gentry-Maharaj A; Glasspool R; Goranova T; Greene CS; Haluska P; Harris HR; Hendley J; Hernandez BY; Herpel E; Jimenez-Linan M; Karpinskyj C; Kaufmann SH; Keeney GL; Kennedy CJ; Köbel M; Koziak JM; Larson MC; Lester J; Lewsley LA; Lissowska J; Lubiński J; Luk H; Macintyre G; Mahner S; McNeish IA; Menkiszak J; Nevins N; Osorio A; Oszurek O; Palacios J; Hinsley S; Pearce CL; Pike MC; Piskorz AM; Ray-Coquard I; Rhenius V; Rodriguez-Antona C; Sharma R; Sherman ME; De Silva D; Singh N; Sinn P; Slamon D; Song H; Steed H; Stronach EA; Thompson PJ; Tołoczko A; Trabert B; Traficante N; Tseng CC; Widschwendter M; Wilkens LR; Winham SJ; Winterhoff B; Beeghly-Fadiel A; Benitez J; Berchuck A; Brenton JD; Brown R; Chang-Claude J; Chenevix-Trench G; deFazio A; Fasching PA; García MJ; Gayther SA; Goodman MT; Gronwald J; Henderson MJ; Karlan BY; Kelemen LE; Menon U; Orsulic S; Pharoah PDP; Wentzensen N; Wu AH; Schildkraut JM; Rossing MA; Konecny GE; Huntsman DG; Huang RY; Goode EL; Ramus SJ; Doherty JA; Bowtell DD; Anglesio MS
Clin Cancer Res; 2020 Oct; 26(20):5411-5423. PubMed ID: 32554541
[TBL] [Abstract][Full Text] [Related]
7. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
8. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
[TBL] [Abstract][Full Text] [Related]
10. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
11. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.
Schwede M; Spentzos D; Bentink S; Hofmann O; Haibe-Kains B; Harrington D; Quackenbush J; Culhane AC
PLoS One; 2013; 8(3):e57799. PubMed ID: 23536770
[TBL] [Abstract][Full Text] [Related]
12. Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer.
Tan TZ; Heong V; Ye J; Lim D; Low J; Choolani M; Scott C; Tan DSP; Huang RY
J Pathol; 2019 Mar; 247(3):305-319. PubMed ID: 30374975
[TBL] [Abstract][Full Text] [Related]
13. Circular RNA profiling reveals circRNA1656 as a novel biomarker in high grade serous ovarian cancer.
Gao Y; Zhang C; Liu Y; Wang M
Biosci Trends; 2019 May; 13(2):204-211. PubMed ID: 31019161
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
15. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
16. Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival.
Kernagis DN; Hall AH; Datto MB
J Mol Diagn; 2012; 14(3):214-22. PubMed ID: 22490445
[TBL] [Abstract][Full Text] [Related]
17. Ovarian Cancer: A Heterogeneous Disease.
Kossaï M; Leary A; Scoazec JY; Genestie C
Pathobiology; 2018; 85(1-2):41-49. PubMed ID: 29020678
[TBL] [Abstract][Full Text] [Related]
18. Intraoperative Diagnosis Support Tool for Serous Ovarian Tumors Based on Microarray Data Using Multicategory Machine Learning.
Park JS; Choi SB; Kim HJ; Cho NH; Kim SW; Kim YT; Nam EJ; Chung JW; Kim DW
Int J Gynecol Cancer; 2016 Jan; 26(1):104-13. PubMed ID: 26512784
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.
Furtado LV; Samowitz WS
Virchows Arch; 2017 Aug; 471(2):235-242. PubMed ID: 28551725
[TBL] [Abstract][Full Text] [Related]
20. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
